Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $4.80.

A number of brokerages have recently issued reports on KPTI. Royal Bank of Canada reiterated an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. StockNews.com upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Robert W. Baird cut their price objective on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th.

Karyopharm Therapeutics Stock Up 1.7 %

NASDAQ:KPTI opened at $0.86 on Friday. The firm has a market cap of $107.37 million, a PE ratio of -0.73 and a beta of 0.20. Karyopharm Therapeutics has a 12 month low of $0.62 and a 12 month high of $1.95. The company’s 50-day moving average price is $0.79 and its two-hundred day moving average price is $0.97.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09. The company had revenue of $42.79 million for the quarter, compared to analyst estimates of $36.07 million. On average, research analysts expect that Karyopharm Therapeutics will post -0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several large investors have recently bought and sold shares of KPTI. AQR Capital Management LLC raised its holdings in Karyopharm Therapeutics by 494.5% in the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock worth $649,000 after purchasing an additional 622,194 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in Karyopharm Therapeutics in the second quarter worth $494,000. Ikarian Capital LLC raised its holdings in Karyopharm Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock worth $618,000 after purchasing an additional 9,355 shares during the period. Exchange Traded Concepts LLC raised its holdings in Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after purchasing an additional 56,613 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in Karyopharm Therapeutics in the second quarter worth $167,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).